Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
132 participants
OBSERVATIONAL
2018-02-22
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Amygdala Neurofeedback on Depressive Symptoms
NCT02709161
Self-Face Recognition After Face Transplantation
NCT03027141
Affective Processing in Depression and Epilepsy
NCT00855725
Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression
NCT06219681
Development Of New Techniques For Functional Magnetic Resonance Imaging Of The Brain
NCT00593931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
trans men
fMRI: body morph test and neurocognitive testing
fMRI
fMRI: body morph test and neurocognitive testing
trans women
fMRI: body morph test and neurocognitive testing
fMRI
fMRI: body morph test and neurocognitive testing
homosexual cisgender men
fMRI: body morph test and neurocognitive testing
fMRI
fMRI: body morph test and neurocognitive testing
homosexual cisgender women
fMRI: body morph test and neurocognitive testing
fMRI
fMRI: body morph test and neurocognitive testing
cisgender women
fMRI: body morph test and neurocognitive testing
fMRI
fMRI: body morph test and neurocognitive testing
cisgender men
fMRI: body morph test and neurocognitive testing
fMRI
fMRI: body morph test and neurocognitive testing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fMRI
fMRI: body morph test and neurocognitive testing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must meet Diagnostic and Statistical Manual-5 criteria for GD (302.85)
* Intelligence quotient (IQ) \> 80
Participants with GD
* Females and males from any racial or ethnic background, between the ages of 18 and 40.
* IQ \> 80
Control participants
Exclusion Criteria
* Previous sex reassignment surgery
* Oral contraceptives
* Participants with GD are not be taking any other psychotropic medication. (No participant will be recommended to discontinue or taper medications for the purpose of participating in the study.)
* Irregular menstrual cycles
Control participants
* Psychiatric medications
* A score of ≥ 1 standard deviation higher than population norms on the MADRS depression or the Hamilton anxiety scale (HAMA)
* Sex hormone treatment
* Irregular menstrual cycles
* Any known chromosomal or hormonal disorder
* Current substance abuse or dependence
* Current neurological disorder or psychiatric disorder
* Pregnancy
* Current major medical disorders that may affect cerebral metabolism such as diabetes or thyroid disorders
* Head trauma associated with loss of consciousness
* HIV positive individuals
* Individuals with ferromagnetic metal implantations or devices. This includes any electronic implants or devices, braces, infusion pumps, aneurysm clips, metal fragments or foreign bodies, metal prostheses, joints, rods or plates
* Visual acuity worse than 20/35 for each eye as determined by Snellen close vision acuity chart. Acuity may be met with corrective lenses
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jamie Feusner
Professor of Psychiatry and Biobehavioral Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.